Ayala Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ayala Pharmaceuticals, Inc.
The companies’ respective gamma-secretase inhibitors provided positive data for desmoid tumors at the ESMO congress but SpringWork’s nirogacestat impressed the most.
The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.
The pharma, biotech and allied industries came back together in London on 2 December to celebrate a year of exceptional achievement at the 17th Annual Scrip Awards, hosted by the journalist and broadcaster Amol Rajan.
The cancer drug developer raised $55m. Also, Lyra raised $56m in the last of four biopharma IPOs in April, Biogen sold $3bn worth of debt, Oberland raised a $1.05bn fund and Praxis launched with more than $100m.
Drug Discovery Tools
- Drug Discovery Tools